Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gilead Sciences (NQ: GILD ) 83.94 +0.10 (+0.12%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Gilead Sciences < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Biotech Boom Ahead? Key Stocks and ETFs to Watch Now September 23, 2024 The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital. Via MarketBeat Topics ETFs Economy Exposures Economy Interest Rates Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial September 12, 2024 From Gilead Sciences, Inc. Via Business Wire Biotech Breakout: Stocks for Your Watchlist September 12, 2024 The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. Via MarketBeat Topics ETFs Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies September 10, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer September 05, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead Sciences to Present at Upcoming Investor Conferences August 21, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA August 14, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead Sciences Announces Second Quarter 2024 Financial Results August 08, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 July 25, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline July 25, 2024 From Gilead Sciences, Inc. Via Business Wire Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 July 24, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia July 22, 2024 From Gilead Sciences, Inc. Via Business Wire Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025 July 17, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024 July 16, 2024 From Gilead Sciences, Inc. Via Business Wire Positive News is Driving This Cancer Drug Maker’s Stock Higher July 15, 2024 IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather Via MarketBeat MarketBeat Week in Review – 6/17 - 6/21 June 22, 2024 Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally Via MarketBeat Topics Economy Stocks Exposures Interest Rates US Equities Gilead Sciences Stock Surges on HIV Treatment Trial Success June 21, 2024 Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. Via MarketBeat Exposures Product Safety Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention June 20, 2024 From Gilead Sciences, Inc. Via Business Wire Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END Via FinancialNewsMedia Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 From FN Media Group LLC Via GlobeNewswire New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment June 14, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA June 06, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis June 05, 2024 From Gilead Sciences, Inc. Via Business Wire Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia June 03, 2024 From Gilead Sciences, Inc. Via Business Wire Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma June 03, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer June 02, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers June 01, 2024 From Gilead Sciences, Inc. Via Business Wire EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024 May 31, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead Provides Update on Phase 3 TROPiCS-04 Study May 30, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024 May 22, 2024 From Gilead Sciences, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.